A Phase II, Multicenter, International Study of Lenalidomide and Rituximab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Non-Hodgkin Lymphoma, Transformed Large Cell Lymphoma, and Grade 3 Follicular Lymphoma
The number of patients from Asia who are treated at MD Anderson is limited due to (1) lack of incentive to referring physicians from Asia; (2) poor final clinical outcome due to limited survival in some cancers; (3) requirement for prohibitively long transatlantic travel; and (4) lack of financial support. To overcome these barriers and to attract more patients from Asia to MD Anderson Cancer Center we need to conduct clinical trials with oral novel therapies that are not yet available in Asia using our well-established Sister Institutions in Asia as pilot sites for the studies. B-cell non-Hodgkin lymphoma (B-NHL) is an ideal disease for conducting these studies, as there has been rapid therapeutic progress in this field and patients have long survival times. In addition, our studies in B-NHL have already been done in a Western population and have shown good efficacy and minimal toxicity. Rituximab, a chimeric anti-CD20 antibody available in China and lenalidomide, an immunomodulatory agent, are associated with direct induction of apoptosis and antibody-dependent cell-mediated cytotoxicity with clinical efficacy in B-NHLs.